Tekin Akpolat1, Emre Erdem, Türkan Aydogdu. 1. Department of Nephrology, Ondokuz Mayis University School of Medicine, Samsun, Turkey. tekinakpolat @ yahoo.com
Abstract
BACKGROUND: Encouragement of home blood pressure (BP) monitoring has a great potential to improve hypertension control rates. The purpose of this study was to test validation of the Omron M3 Intellisense (HEM-7051-E) upper arm BP measuring monitor for self-measurement according to the European Society of Hypertension International Protocol revision 2010 (ESH-IP2) in stage 3-5 chronic kidney disease (CKD) patients. METHODS: 66 patients having CKD stage 3-5 were included in the study. Nine consecutive measurements were made according to the ESH-IP2 protocol. RESULTS: The Omron M3 Intellisense device fulfills the validation criteria of the ESH-IP2 for stage 3-5 CKD patients. CONCLUSION: Although arterial stiffness can affect accurate BP measurement, there are limited data regarding the use of automated oscillometric devices in CKD. To our knowledge, this is the first study investigating validation of an oscillometric device in stage 3-5 predialysis CKD patients. This study validates the Omron M3 Intellisense upper arm device for stage 3-5 CKD patients. New validation studies investigating other oscillometric sphygmomanometers for CKD patients and involvement of nephrologists in these studies have great potential to increase patient care in CKD.
BACKGROUND: Encouragement of home blood pressure (BP) monitoring has a great potential to improve hypertension control rates. The purpose of this study was to test validation of the Omron M3 Intellisense (HEM-7051-E) upper arm BP measuring monitor for self-measurement according to the European Society of Hypertension International Protocol revision 2010 (ESH-IP2) in stage 3-5 chronic kidney disease (CKD) patients. METHODS: 66 patients having CKD stage 3-5 were included in the study. Nine consecutive measurements were made according to the ESH-IP2 protocol. RESULTS: The Omron M3 Intellisense device fulfills the validation criteria of the ESH-IP2 for stage 3-5 CKD patients. CONCLUSION: Although arterial stiffness can affect accurate BP measurement, there are limited data regarding the use of automated oscillometric devices in CKD. To our knowledge, this is the first study investigating validation of an oscillometric device in stage 3-5 predialysis CKD patients. This study validates the Omron M3 Intellisense upper arm device for stage 3-5 CKD patients. New validation studies investigating other oscillometric sphygmomanometers for CKD patients and involvement of nephrologists in these studies have great potential to increase patient care in CKD.
Authors: Jordana B Cohen; Tiffany C Wong; Bruce S Alpert; Raymond R Townsend Journal: J Clin Hypertens (Greenwich) Date: 2017-01-12 Impact factor: 3.738
Authors: Michael A Weber; Christopher R Chapple; Christian Gratzke; Sender Herschorn; Dudley Robinson; Jeffrey M Frankel; Arwin M Ridder; Matthias Stoelzel; Asha Paireddy; Robert van Maanen; William B White Journal: Blood Press Monit Date: 2018-06 Impact factor: 1.444
Authors: Victoria Mazoteras-Pardo; Ricardo Becerro-De-Bengoa-Vallejo; Marta Elena Losa-Iglesias; Daniel López-López; Patricia Palomo-López; David Rodríguez-Sanz; César Calvo-Lobo Journal: JMIR Mhealth Uhealth Date: 2019-03-19 Impact factor: 4.773
Authors: Victoria Mazoteras-Pardo; Ricardo Becerro-De-Bengoa-Vallejo; Marta Elena Losa-Iglesias; Daniel López-López; Patricia Palomo-López; David Rodríguez-Sanz; César Calvo-Lobo Journal: JMIR Mhealth Uhealth Date: 2018-10-25 Impact factor: 4.773
Authors: Victoria Mazoteras-Pardo; Ricardo Becerro-De-Bengoa-Vallejo; Marta Elena Losa-Iglesias; Daniel López-López; David Rodríguez-Sanz; Israel Casado-Hernández; Cesar Calvo-Lobo; Patricia Palomo-López Journal: J Med Internet Res Date: 2019-12-02 Impact factor: 5.428
Authors: Victoria Mazoteras-Pardo; Ricardo Becerro-De-Bengoa-Vallejo; Marta Elena Losa-Iglesias; Daniel López-López; César Calvo-Lobo; David Rodríguez-Sanz; Eva María Martínez-Jiménez; Patricia Palomo-López Journal: JMIR Mhealth Uhealth Date: 2020-04-02 Impact factor: 4.773